🔔Stock Alerts via Telegram — Free for All Users

NUTX Stock Risk & Deep Value Analysis

Nutex Health Inc

Healthcare • Medical Care Facilities

DVR Score

2.0

out of 10

Risk Trap

What You Need to Know About NUTX Stock

We analyzed Nutex Health Inc using our deep value framework. Sign in to see our full verdict and DVR Score.

We ran NUTX through our deep value framework — analyzing financial health, distress signals, competitive moat, and risk factors. Our risk assessment: Aggressive. Here's what we found.

Updated Mar 25, 2026Run Fresh Analysis →

NUTX Risk Analysis & Red Flags

What Could Go Wrong

The company's primary revenue generation strategy, heavily reliant on arbitration practices, faces significant regulatory uncertainty from the No Surprises Act. An adverse ruling or stricter enforcement could severely diminish its revenue, lead to substantial losses, and necessitate highly dilutive capital raises to maintain operations.

Risk Matrix

Overall

Aggressive

Financial

High

Market

High

Competitive

High

Execution

Medium

Regulatory

High

Red Flags

  • Substantial Q4 2025 revenue and EPS miss against estimates.

  • Explicit and critical regulatory risk to arbitration revenue sustainability under No Surprises Act.

  • Unavailability of operating and free cash flow data for a capital-intensive business model.

  • High forward P/E (30.00) relative to trailing P/E (10.08-11.31) suggests expected future growth deceleration or earnings compression.

  • Potential future dilution from the $99.31M ESOP shelf.

Upcoming Risk Events

  • 📅

    Adverse regulatory rulings or unfavorable policy changes impacting arbitration revenue

  • 📅

    Further significant quarterly revenue and EPS misses

When to Reconsider

  • 🚪

    Quarterly revenue declines year-over-year or consecutive quarters of significant misses.

  • 🚪

    Reported operating or free cash flow turns significantly negative for two consecutive quarters.

  • 🚪

    Adverse regulatory rulings or legislative changes regarding arbitration practices that materially impact revenue.

Unlock NUTX Risk Analysis & Red Flags

Create a free account to see the full analysis

What Does Nutex Health Inc (NUTX) Do?

Market Cap

$618.94M

Sector

Healthcare

Industry

Medical Care Facilities

Employees

880

Nutex Health Inc. operates as a healthcare services and operations company in the United States. It operates through three segments: Hospital, Population Health Management (PHM), and Real Estate. The Hospital segment develops and operates a network of micro hospitals, specialty hospitals, and hospital outpatient departments that offer healthcare services, including emergency room care, inpatient care, and behavioural health. It also provides imaging services, such as CT scan, X-ray, MRI, ultrasound, etc.; laboratory services; and onsite inpatient pharmacies. The PHM segment provides management, administrative, and other support services to its affiliated hospitals and physician groups by establishing and operating provider networks, such as independent physician associations (IPAs); and a cloud-based technology platform for IPAs. The Real Estate segment owns and leases land and hospital buildings. The company was founded in 2011 and is headquartered in Houston, Texas.

Visit Nutex Health Inc Website

Investment Thesis

Nutex Health has demonstrated significant top-line growth and achieved profitability, with a healthy balance sheet, suggesting a recovery from prior financial challenges. If the company can successfully navigate the regulatory risks associated with the No Surprises Act and demonstrate sustainable cash flow generation, its niche in micro-hospitals could provide a platform for further, albeit high-risk, growth.

Is NUTX Stock Undervalued?

Nutex Health Inc. (NUTX) presents a mixed financial picture that, while improved from past assessments, still carries substantial risk for 10x growth. The company reported significant full-year 2025 revenue growth (+82.4% YoY) and achieved positive net income ($70.8M), with healthy balance sheet ratios (current ratio 3.41, D/E 0.70). These metrics suggest a stronger fundamental position than previously indicated. However, a significant Q4 2025 revenue and EPS miss raises concerns about recent performance. Critically, the explicit regulatory risk surrounding arbitration revenue under the No Surprises Act poses a direct threat to the sustainability of its business model. The absence of reported cash flow data for a capital-intensive operation is a major red flag, hindering a comprehensive assessment of financial health. While some fundamental improvements exist, the severe regulatory overhang and opaque cash generation severely limit its potential for exponential growth and market leadership within 3-5 years.

Unlock the full AI analysis for NUTX

Get the complete DVR score, risk analysis, and more

📈

Unlock the full report

Create a free account to see the DVR score, risk flags, and AI analysis.

NUTX Price Targets & Strategy

12-Month Target

$150.00

Bull Case

$200.00

Bear Case

$50.00

Valuation Basis

Based on 30x forward P/E applied to estimated $5.00 FY26 EPS, reflecting Q4 miss and regulatory headwinds.

Entry Strategy

Dollar-cost average on dips below $90, or await greater clarity on No Surprises Act arbitration impact.

Exit Strategy

Take profit at $150-$200. Set a stop-loss order if the price falls below $75, indicating deteriorating sentiment or fundamentals.

Portfolio Allocation

5% for aggressive risk tolerance.

Price Targets & Strategy

Upgrade to Premium for price targets and entry/exit strategies

Is NUTX Financially Healthy?

Valuation

P/E Ratio

9.89

Forward P/E

30.00

Profitability

Net Margin

10.76%

Return on Equity

42.08%

Revenue Growth

82.40%

EPS

$12.01

Balance Sheet

Current Ratio

3.41

Quick Ratio

3.39

Debt/Equity

0.70

Total Debt

$43.50M

Cash Flow

Operating Cash Flow

$248.10M

EBITDA

$259.60M

Other

Beta (Volatility)

0.03

Does NUTX Have a Competitive Moat?

Sign in to unlock

Moat Rating

⚪ None

Moat Trend

Eroding

The company lacks a durable economic moat. Its reliance on arbitration as a revenue strategy is currently under regulatory threat, making its business model highly susceptible to external changes. There are no clear indications of network effects, switching costs, strong brand power, or proprietary technology creating a sustainable advantage.

Moat Erosion Risks

  • Adverse changes to healthcare legislation and regulatory environment, particularly regarding arbitration.
  • Increased competition in the micro-hospital and emergency care sector.
  • Inability to diversify revenue streams away from regulatory-sensitive models.

NUTX Competitive Moat Analysis

Sign up to see competitive advantages

NUTX Market Intelligence

Sentiment & Insider Activity

Social Sentiment

Neutral (no specific data provided)

Institutional Sentiment

Mixed; recent institutional stake (Pertento Partners) is positive, but analyst sentiment has seen a target cut (Maxim Group) and a strong-buy to hold downgrade (Wall Street Zen).

Insider Activity (Form 4)

President Warren Hosseinion bought 252 shares ($23,706) on March 19, 2026.

Options Flow

Normal options activity (no specific unusual activity provided)

Earnings Intelligence

Next Earnings

Q1 2026 (Expected May 2026, date TBD)

Surprise Probability

Medium

Historical Earnings Pattern

Unpredictable (historical reaction patterns not provided in research)

Key Metrics to Watch

Revenue growth (YoY and QoQ)Net margin and profitability trendsCash Flow from Operations (if disclosed)Management guidance on regulatory impacts

Competitive Position

Top Competitor

No specific best-in-class competitor provided in research.

Market Share Trend

Stable/Unknown (no data provided)

Valuation vs Peers

Unable to compare without peer valuation data or sector medians.

Competitive Advantages

  • Claimed 80%+ win rate in arbitration (though sustainability is questioned)
  • Focus on micro-hospital and emergency care model

Market Intelligence

Get sentiment, earnings intel, and peer analysis with Premium

What Could Drive NUTX Stock Higher?

Near-Term (0-6 months)

  • Q1 2026 Earnings (Expected May 2026)
  • Clarity or favorable resolution regarding No Surprises Act arbitration rules

Medium-Term (6-18 months)

  • Continued expansion of micro-hospital network in new geographies
  • Announcements of new strategic partnerships to diversify revenue streams

Long-Term (18+ months)

  • Establishment of a durable competitive advantage beyond arbitration dependency
  • Transition towards more value-based care models for long-term sustainability

Catalysts & Growth Drivers

Upgrade to Premium to see catalysts

What's the Bull Case for NUTX?

  • Positive and growing Free Cash Flow (FCF) reported in upcoming earnings.

  • Clear and favorable resolution or guidance from regulators on the No Surprises Act impact.

  • Diversification of revenue sources beyond arbitration.

Bull Case Analysis

See what could go right with Premium

Competing with NUTX

See how Nutex Health Inc compares to related companies

CompanyMarket CapDVR ScoreP/ERevenueProfit MarginRev Growth

Nutex Health Inc

NUTX

$618.9M2.09.9$875.3M10.8%82.4%

AbbVie Inc

ABBV

$403.8B0.1171.8Compare →

Johnson & Johnson

JNJ

1.0Compare →

Eli Lilly and Co

LLY

$965.0B0.552.6Compare →

Pfizer Inc

PFE

$150.6B0.219.4$62.6B12.4%-1.6%Compare →

UnitedHealth Group Inc

UNH

$276.2B0.322.9$113.7B2.7%1181.0%Compare →

📊 Explore More Stock Analysis

Get comprehensive Deep Value Reports for thousands of stocks. Research risk, financial health, and investment potential with our AI-powered analysis.

FAQ

What is the DVR Score for Nutex Health Inc (NUTX)?

As of March 25, 2026, Nutex Health Inc has a DVR Score of 2.0 out of 10, placing it in the "Risk Trap" category. This score is generated by our AI-powered deep value analysis framework that evaluates growth potential, financial health, competitive moat, and risk factors.

What is the market capitalization of Nutex Health Inc?

Nutex Health Inc's market capitalization is approximately $618.9M. The company operates in the Healthcare sector within the Medical Care Facilities industry.

What ticker symbol does Nutex Health Inc use?

NUTX is the ticker symbol for Nutex Health Inc. The company trades on the NCM.

What is the risk level for NUTX stock?

Our analysis rates Nutex Health Inc's overall risk as Aggressive. This assessment considers execution risk, market risk, financial risk, competitive risk, and regulatory risk. For a full breakdown, see the risk analysis section above.

What is the P/E ratio of NUTX?

Nutex Health Inc currently has a price-to-earnings (P/E) ratio of 9.9. This is below the market average, which could indicate the stock is undervalued or facing headwinds.

Is Nutex Health Inc's revenue growing?

Nutex Health Inc has reported revenue growth of 82.4%. The company is showing strong top-line momentum.

Is NUTX stock profitable?

Nutex Health Inc has a profit margin of 10.8%. The company is profitable but margins are modest.

How often is the NUTX DVR analysis updated?

Our AI-powered analysis of Nutex Health Inc is refreshed regularly to incorporate the latest financial data, market conditions, and news. The most recent update was on March 25, 2026.

Important Disclaimer – Not Financial Advice

Deep Value Reports is an independent research platform for educational and informational purposes only. We are not financial advisors, investment advisors, or licensed professionals. The analysis, scores, and information provided on this page for NUTX (Nutex Health Inc) should not be construed as personalized investment advice, a recommendation to buy or sell any security, or an offer to provide investment advisory services.

All investments involve risk, including the potential loss of principal. Past performance does not guarantee future results. Always conduct your own research, consider your financial situation, and consult with a qualified financial advisor before making any investment decisions.

Navigated to NUTX Stock Risk & Deep Value Analysis